Therapeutics Letter en español # 4, febrero 1995

Traducido con permiso de Therapeutics Letter, número 4, febrero 1995
http://www.ti.ubc.ca/pages/letter4.html

Therapeutics Letter en español # 3, diciembre 1994

Traducido con permiso de Therapeutics Letter, número 3, diciembre 1994
http://www.ti.ubc.ca/pages/letter3.html

Therapeutics Letter en español # 2, noviembre 1994

Traducido con permiso de Therapeutics Letter, número 2, noviembre 1994
http://www.ti.ubc.ca/pages/letter2.html

Therapeutics Letter en español # 1

Traducido con permiso de Therapeutics Letter, número 1, octubre 1994: http://www.ti.ubc.ca/pages/letter1.html

Therapeutics Letter 16, November/December 1996

What has changed in the past year?

Each year we review therapeutic issues covered in the past and identify new clinical trials that reinforce or change our recommendations. Our last Review and Update, Letter 9, was in September 1995. In this issue we review thirteen recent clinical trials that pertain to nine previous Letters.

Therapeutics Letter, issue 17, January 1997

• Famciclovir (Famvir®) and Valacyclovir (Valtrex®)
• Torsemide (Demadex®)
• Etodolac (Ultradol®)
• Naltrexone (Revia®)

Famciclovir (Famvir®) and Valacyclovir (Valtrex®)

Both are new antiherpesvi

Therapeutics Letter, issue 18, February / March / April 1997

Therapeutics Letter, issue 20, July - August 1997

Alendronate (Fosamax®)

Dorzolamide (Trusopt®)

Acarbose (Prandase®)

Olanzapine (Zyprexa®)

Alendronate (Fosamax®)

Therapeutics Letter, issue 21, September-October 1997

It is difficult to identify a condition in developed countries that presents such a mix of lethality, prevalence, and neglect, despite effective and readily available interventions (1).

So begins the U.S. clinical practice guideline on smoking cessation. Canadian preventive experts give clinical smoking cessation an "A" recommendation (good evidence for effectiveness) (2). Importantly, smokers place a physician-based approach at the top of their list of methods to stop smoking (3).